VEGF in Signaling and Disease: Beyond Discovery and Development.

Published on Mar 7, 2019in Cell38.637
· DOI :10.1016/J.CELL.2019.01.021
Rajendra S. Apte37
Estimated H-index: 37
(WashU: Washington University in St. Louis),
Daniel S. Chen40
Estimated H-index: 40
Napoleone Ferrara179
Estimated H-index: 179
(UCSD: University of California, San Diego)
The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.
Figures & Tables
📖 Papers frequently viewed together
506 Citations
25.8k Citations
3,168 Citations
#1Kimberly Spooner (USYD: University of Sydney)H-Index: 5
#2Thomas Hong (Vision-Sciences, Inc.)H-Index: 18
Last. Andrew Chang (USYD: University of Sydney)H-Index: 20
view all 4 authors...
: To systematically review anatomical and functional outcomes of switching therapy from bevacizumab and/or ranibizumab to aflibercept in patients with persistent macular oedema secondary to retinal vein occlusions (RVO). A systematic search of aflibercept for the treatment of persistent macular oedema secondary to branch and central RVO was performed in EMBASE, PubMed and Cochrane databases prior to June 2017. The main outcome variables described were best-corrected visual acuity (BCVA) and cent...
5 CitationsSource
#1Norimitsu Ban (WashU: Washington University in St. Louis)H-Index: 9
#2Tae Jun Lee (WashU: Washington University in St. Louis)H-Index: 4
Last. Rajendra S. ApteH-Index: 37
view all 11 authors...
: Advanced age-related macular degeneration (AMD), the leading cause of blindness among people over 50 years of age, is characterized by atrophic neurodegeneration or pathologic angiogenesis. Early AMD is characterized by extracellular cholesterol-rich deposits underneath the retinal pigment epithelium (RPE) called drusen or in the subretinal space called subretinal drusenoid deposits (SDD) that drive disease progression. However, mechanisms of drusen and SDD biogenesis remain poorly understood....
21 CitationsSource
: Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway have demonstrated durable clinical benefit in some patients. However, CIT combinations may create a more favorable environment in which to maximize the potential of the immune system to eliminate cancer. Here we describe 3 key mechanisms related to vascular endothelial growth factor (VEGF)-mediated immunosuppression: inhibition o...
57 CitationsSource
#1Colin D. Weekes (Harvard University)H-Index: 26
#2Lee S. Rosen (UCLA: University of California, Los Angeles)H-Index: 56
Last. Alberto BessudoH-Index: 2
view all 17 authors...
Purpose MINT1526A is a monoclonal antibody that blocks the interaction of integrin alpha 5 beta 1 (α5β1) with its extracellular matrix ligands. This phase I study evaluated the safety and pharmacokinetics of MINT1526A with or without bevacizumab in patients with advanced solid tumors.
7 CitationsSource
#1Mark A. SocinskiH-Index: 76
#2Robert M. JotteH-Index: 22
Last. Martin ReckH-Index: 71
view all 20 authors...
Abstract Background The cancer-cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) who had not previously received chemotherapy. Methods We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), beva...
1,103 CitationsSource
#1David F. McDermott (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 93
#2Mahrukh Huseni (Genentech)H-Index: 15
Last. Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
view all 32 authors...
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69–1.45) and 1.19 (...
369 CitationsSource
#1Frank G. Holz (University of Bonn)H-Index: 88
#2Srinivas R. Sadda (UCLA: University of California, Los Angeles)H-Index: 79
Last. Neil M. Bressler (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 89
view all 14 authors...
Importance Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials. Objective To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA. Design, Setting, and Participants Two identically designed phase 3 double-masked, randomized, sham-control...
104 CitationsSource
#1Da LongH-Index: 3
#2Yogita KananH-Index: 4
Last. Peter A. CampochiaroH-Index: 121
view all 9 authors...
: Intraocular injections of VEGF-neutralizing proteins provide tremendous benefits in patients with choroidal neovascularization (NV) due to age-related macular degeneration (AMD), but during treatment some patients develop retinal atrophy. Suggesting that VEGF is a survival factor for retinal neurons, a clinical trial group attributed retinal atrophy to VEGF suppression and cautioned against frequent anti-VEGF injections. This recommendation may contribute to poor outcomes in clinical practice ...
13 CitationsSource
#1Yoshiro Itatani (Kyoto University)H-Index: 16
#2Kenji Kawada (Kyoto University)H-Index: 27
Last. Yoshiharu Sakai (Kyoto University)H-Index: 60
view all 4 authors...
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and p...
52 CitationsSource
The mammalian prokineticins family comprises two conserved proteins, EG-VEGF/PROK1 and Bv8/PROK2, and their two highly related G protein-coupled receptors, PKR1 and PKR2. This signaling system has been linked to several important biological functions, including gastrointestinal tract motility, regulation of circadian rhythms, neurogenesis, angiogenesis and cancer progression, hematopoiesis, and nociception. Mutations in PKR2 or Bv8/PROK2 have been associated with Kallmann syndrome, a development...
20 CitationsSource
Cited By274
#1Bohui Sun (PKU: Peking University)H-Index: 1
#2Yangjia Liu (PKU: Peking University)
Last. Feng Chen (PKU: Peking University)H-Index: 98
view all 8 authors...
Vascular endothelial growth factor A (VEGFA) is a crucial growth factor, which participates in multiple processes of human growth and development, such as angiogenesis and osteogenesis and is also necessary for development of palate. The purpose of this study was to investigate the effect of a rare VEGFA mutation (NM_001025366.2 773 T > C p.Val258Ala) on the cell functions and osteogenesis. Here, we found that the VEGFA mutation has adverse effects on the function of human embryonic palatal plat...
#2Gang WangH-Index: 2
Last. Mao LuoH-Index: 2
view all 5 authors...
Abstract Interactions between vascular smooth muscle cells (VSMCs), endothelial cells (ECs), pericytes (PCs) and macrophages (MФ), the major components of blood vessels, play a crucial role in maintaining vascular structural and functional homeostasis. Low-density lipoprotein (LDL) receptor-related protein-1 (LRP1), a transmembrane receptor protein belonging to the LDL receptor family, plays multifunctional roles in maintaining endocytosis, homeostasis, and signal transduction. Accumulating evid...
#2Vladimir Hanes (Amgen)H-Index: 7
ABP 215 (MVASI™, Amgen, Thousand Oaks, CA; MVASI™, Amgen Europe B.V., Netherlands) is a biosimilar to bevacizumab (Avastin®, Genentech, South San Francisco, CA) reference product (RP), a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Here we provide a brief overview of the totality of evidence that supported the approval of ABP 215, along with practical considerations to ensure safe and effective administration. ABP 215 has been shown to be highly similar to the RP,...
#1Da-Peng WangH-Index: 4
#2Kai-Yan JinH-Index: 1
Last. Jian HaiH-Index: 5
view all 6 authors...
#1Manjing Li (Soochow University (Suzhou))
#2Zhaojian Xu (Soochow University (Suzhou))
Last. Yuanyuan Su (SYSU: Sun Yat-sen University)H-Index: 40
view all 11 authors...
Choroidal neovascularization (CNV) is the leading cause of vision loss in many blinding diseases, but current antiangiogenic therapies with invasively intravitreal injection suffer from poor patient compliance and a rate of devastating ocular complications. Here, we develop an alternative antiangiogenic agent based on hybrid cell-membrane-cloaked nanoparticles for noninvasively targeted treatment of CNV. The retinal endotheliocyte membrane coating provides as-fabricated nanoagents with homotypic...
#1Xian-Bin Kong (Tianjin University of Traditional Chinese Medicine)H-Index: 1
#2Chuanxin Liu (Beijing University of Chinese Medicine)H-Index: 2
Last. Jingyan Meng (Tianjin University of Traditional Chinese Medicine)
view all 10 authors...
#1Hong Xin (UCSD: University of California, San Diego)H-Index: 2
#2Nilima Biswas (UCSD: University of California, San Diego)H-Index: 16
Last. Napoleone Ferrara (UCSD: University of California, San Diego)H-Index: 179
view all 7 authors...
Neovascularization is a key feature of ischemic retinal diseases and the wet form of age-related macular degeneration (AMD), all leading causes of severe vision loss. Vascular endothelial growth factor (VEGF) inhibitors have transformed the treatment of these disorders. Millions of patients have been treated with these drugs worldwide. However, in real-life clinical settings, many patients do not experience the same degree of benefit observed in clinical trials, in part because they receive fewe...
#1Bo Ren (Chinese PLA General Hospital)
#2Que Feng (Chinese PLA General Hospital)
Last. Yafan Song (Chinese PLA General Hospital)
view all 13 authors...
BACKGROUND Anti-vascular endothelial growth factor (VEGF) has been used as a therapeutic drug for the treatment of some human diseases. However, no systematic evidence is performed for assessing the role of VEGF in periodontitis. We carried out a comprehensive analysis to explore the role of VEGF in patients with periodontitis. METHODS Multiple databases were searched for eligible studies. The pooled standardized mean difference (SMD) and odds ratio (OR) with the corresponding 95% confidence int...
Last. Ki-Tae HaH-Index: 23
view all 6 authors...
Angiogenesis, a fundamental process in human physiology and pathology, has attracted considerable attention owing to its potential as a therapeutic strategy. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are deemed major mediators of angiogenesis. To date, inhibition of the VEGF-A/VEGFR-2 axis has been an effective strategy employed in the development of anticancer drugs. However, some limitations, such as low efficacy and side effects, need to be addressed. Several drug can...
#1Massimo M. Onesto (UW: University of Wisconsin-Madison)H-Index: 1
#2Caitlin A Short (UW: University of Wisconsin-Madison)H-Index: 1
Last. Timothy M. Gomez (UW: University of Wisconsin-Madison)H-Index: 28
view all 5 authors...
Growth cones at the tips of extending axons navigate through developing organisms by probing extracellular cues, which guide them through intermediate steps and onto final synaptic target sites. Widespread focus on a few guidance cue families has historically overshadowed potentially crucial roles of less well-studied growth factors in axon guidance. In fact, recent evidence suggests that a variety of growth factors have the ability to guide axons, affecting the targeting and morphogenesis of gr...